Editorial & Opinion
Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer.
| العنوان: | Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer. |
|---|---|
| المؤلفون: | Mortensen HR; Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark., Populaire P; University Hospitals Leuven, Department of Radiation Oncology, Belgium; KU Leuven- University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium., Hoffmann L; Department of Oncology and Medical Physics, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark., Moeller DS; Department of Oncology and Medical Physics, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark., Appelt A; University of Leeds, Leeds, UK., Nafteux P; University Hospitals Leuven, Department of Thoracic Surgery, Belgium., Muijs CT; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Grau C; Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark., Hawkins MA; Department of Medical Physics and Biomedical Engineering, University College London, London, UK., Troost EGC; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay Helmholtz-Zentrum Dresden-Rossendorf, Germany., Defraene G; KU Leuven- University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium., Canters R; Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, the Netherlands., Clarke CS; Research Dept. of Primary Care and Population Health, University College London, London, UK., Weber DC; Center for Proton Therapy, Paul Scherrer Institut, Villigen, Switzerland; Radiation Oncology Department, University Hospital Zurich, Zurich, Switzerland., Korevaar EW; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Haustermans K; University Hospitals Leuven, Department of Radiation Oncology, Belgium; KU Leuven- University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium., Nordsmark M; Department of Oncology and Medical Physics, Aarhus University Hospital, Aarhus, Denmark., Gebski V; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia., Achiam MP; Dept. Surgery and Transplantation, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Markar SR; Department of General Surgery, Oxford University Hospitals, Oxford, UK; Nuffield Department of Surgery, University of Oxford, Oxford, UK., Radhakrishna G; The Christie, Manchester, United Kingdom., Berbee M; Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Scartoni D; Proton Therapy Center, Azienda Provinciale per i Servizi Sanitari, Trento, Italy., Orlandi E; National Center for Oncological Hadrontherapy (CNAO), Radiation Oncology Clinical Department, Pavia, Italy., Doyen J; Centre Antoine Lacassagne, Nice, France., Gregoire V; Centre Léon Bérard, 28 rue Laennec, Lyon 69373 Cedex 08, France., Crehange G; PSL Research University, RadiationOncology Department, Institut Curie, Paris/Orsay, France., Langendijk J; Department of Radiation Oncology, UniversityMedicalCentreGroningen, Groningen, The Netherlands., Lorgelly P; University of Auckland, Waipara Taumata Rau, Auckland, New Zealand., Blommenstein HM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, Rotterdam, 3000 DR, The Netherlands; Erasmus Centre for Health Economics Rotterdam, Erasmus University, Rotterdam, The Netherlands., Byskov CS; Department of Oncology and Medical physics, Aarhus University Hospital, Aarhus, Denmark., Ehmsen ML; Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark., Jensen MF; Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark., Freixas GV; Maastro Proton Therapy, Department of Radiation Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., Bütof R; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay Helmholtz-Zentrum Dresden-Rossendorf, Germany. |
| مؤلفون مشاركون: | PROTECT consortium |
| المصدر: | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Jan; Vol. 190, pp. 109980. Date of Electronic Publication: 2023 Nov 05. |
| نوع المنشور: | Clinical Trial Protocol; Letter |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Limerick : Elsevier Scientific Publishers Original Publication: Amsterdam : Elsevier Science Publishers, c1983- |
| مواضيع طبية MeSH: | Esophageal Neoplasms*/surgery , Neoadjuvant Therapy*, Humans ; Chemoradiotherapy ; Esophagectomy ; Protons ; Clinical Trials, Phase III as Topic ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic |
| مستخلص: | Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Hanna Rahbek Mortensen is Co-chair of Patient Involvement Work Package in PROTECT.]. |
| المشرفين على المادة: | 0 (Protons) |
| تواريخ الأحداث: | Date Created: 20231107 Date Completed: 20240220 Latest Revision: 20240405 |
| رمز التحديث: | 20240406 |
| DOI: | 10.1016/j.radonc.2023.109980 |
| PMID: | 37935284 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1879-0887 |
|---|---|
| DOI: | 10.1016/j.radonc.2023.109980 |